Janus
Log In
Log Out
Ticker Symbol:
JNGLX
Fund Type:
  

Management Fee Evaluation


Class D shares

   
Data as of 03/31/2014
Top Holdings
% of Fund
 
Top Holdings as % of Portfolio
26.28%
No Data Available To Display.
Top Industries
% of Fund
Total
No Data Available To Display.
Capitalization Ranges of Equity Holdings
% of Fund
Over $100 Billion
14.36%
$50 Billion to $100 Billion
14.22%
$10 Billion to $50 Billion
30.46%
$5 Billion to $10 Billion
14.18%
$1 Billion to $5 Billion
18.07%
$500 Million to $1 Billion
4.92%
$250 Million to $500 Million
1.52%
$100 Million to $250 Million
0.85%
Under $100 Million
0.28%
N/A
1.14%
Total
100.00%
Asset Allocation
% of Fund
US Common Stock
76.00%
Non-US Common Stock
21.84%
Convertibles
1.10%
Cash & Equivalents
1.06%
Total
100.00%
Regional Exposure
% of Fund
North America
82.10%
Europe
14.72%
Africa/Mideast
1.62%
Asia/Pacific Ex Japan
0.50%
Cash & Equivalents
1.06%
Total
100.00%
Top Countries
% of Fund
United States
77.11%
United Kingdom
6.39%
Canada
5.00%
Switzerland
3.39%
Israel
1.62%
Sweden
1.48%
Belgium
1.29%
Denmark
1.24%
France
0.93%
China
0.34%
Data as of 03/31/2014
Fund Characteristics
12/31/1998
JNGLX
$ 2.02B
18.91
15.76
6.99
$ 44.84
$ 17.82
91
1
44.64%
1.04
68.45%
14.42
 
Annual Fees and Expenses as of 09/30/2013
0.64%
0.23%
0.87%
Total Net Expenses for Janus Global Life Sciences Fund
0.87%
Sales Charge
This is a no-load** share class
NONE
Top 5 Contributors/Detractors as of 03/31/2014
Top 5 Contributors to Performance
Johnson & Johnson
Chimerix, Inc.
Teva Pharmaceutical Industries, Ltd. (ADR)
Aetna, Inc.
Questcor Pharmaceuticals, Inc.
Top 5 Detractors from Performance
Gilead Sciences, Inc.
Pharmacyclics, Inc.
Celgene Corp.
Swedish Orphan Biovitrum AB
Relypsa, Inc.
     
   

This fund may have securities on loan as of the most recent month-end. The fund invests any cash collateral received in connection with loaned securities in Janus Cash Collateral Fund. View holdings for Janus Cash Collateral Fund.

View holdings for Janus Cash Liquidity Fund.

Please consider the charges, risks, expenses and investment objectives carefully before investing. Please see a prospectus , or if available, a summary prospectus containing this and other information. Read it carefully before you invest or send money.

A Fund's performance may be affected by risks that include those associated with nondiversification, non-investment grade debt securities, high-yield/high-risk securities, undervalued or overlooked companies, investments in specific industries or countries and potential conflicts of interest. Additional risks to a Fund may also include, but are not limited to, those associated with investing in foreign securities, emerging markets, initial public offerings, real estate investment trusts (REITs), derivatives, short sales, commodity-linked investments and companies with relatively small market capitalizations. Each Fund has different risks. Please see a Janus prospectus for more information about risks, Fund holdings and other details.

Foreign securities have additional risks including exchange rate changes, political and economic upheaval, the relative lack of information, relatively low market liquidity and the potential lack of strict financial and accounting controls and standards. These risks are magnified in emerging markets. The prices of foreign securities held by the fund, and therefore a fund's performance, may decline in response to such risks.

The use of short sales may cause the fund to have higher expenses than those of other equity funds. Short sales are speculative transactions and involve special risks, including a greater reliance on the investment team's ability to accurately anticipate the future value of a security. The Fund's losses are potentially unlimited in a short sale transaction. The Fund's use of short sales in effect leverages the Fund's portfolio. The Fund's use of leverage may result in risks and can magnify the effect of any losses. There is no assurance that a leveraging strategy will be successful.

The Fund will normally invest at least 80% of its net assets, measured at the time of purchase, in the type of securities described by its name.

Other fees and expenses apply to a continued investment in the Fund and are described in the Fund's current prospectus.

Holdings are subject to change without notice.

Past performance is no guarantee of future results.

A Fund's portfolio may differ significantly from the securities held in the index. An index is unmanaged and not available for direct investment; therefore its performance does not reflect the expenses associated with the active management of an actual portfolio.

Important Characteristic and Risk Definitions.

Janus Distributors LLC